Study concept and design: Magill, Edwards, Neuhauser, Fridkin.
Acquisition, analysis, or interpretation of data: Beldavs, Dumyati, Janelle, Kainer, Lynfield, Nadle, Ray, Richards, Rodriguez, Thompson.
Drafting of the manuscript: Magill.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Magill, Edwards.
Obtained funding: Fridkin.
Administrative, technical, or material support: All authors.
Study supervision: Beldavs, Dumyati, Janelle, Kainer, Lynfield, Nadle, Ray, Richards, Rodriguez, Thompson, Fridkin.
Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Kainer reported that she is a board member, receives lecture and consulting fees from the Infectious Disease Consulting Corporation; and owns stock in the Infectious Disease Consulting Corporation. Dr Lynfield reported that she receives travel support from Parexel. No other disclosures were reported.
Funding/Support: The survey was supported through a cooperative agreement with the Emerging Infections Program. Funds to conduct the survey came from the CDC’s Division of Healthcare Quality Promotion, Division of Preparedness and Emerging Infections, and Office of Antimicrobial Resistance.
Role of Funders/Sponsors: The funding source was the US federal government. Federal government employees led or participated in all aspects of the survey, including design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC/the Agency for Toxic Substances and Disease Registry, or the Department of Veterans Affairs.
Previous Publication: Data included in this manuscript have been previously presented in abstract and oral presentation form at Infectious Disease Week, October 17-21, 2012, San Diego, California. Pediatric data were presented in abstract and poster presentation Infectious Diseases Week, October 2-6, 2013, San Francisco, California. The results of the health care–associated infection component of the survey have been published.18 The antimicrobial use survey was described.39 Some of the data presented herein were included in the CDC report entitled “Vital Signs: Improving Antibiotic Use Among Hospitalized Patients.”6
Survey Team Members: Other members of the prevalence survey team follows: Wendy Bamberg, MD, and Julie Mullica, MPH (Colorado Department of Public Health and Environment, Denver); Richard Melchreit, MD, and Meghan Maloney, MPH (Connecticut Department of Public Health, Hartford); Lewis Perry, RN, MPH, and Nancy White, RN, BSN, CIC (Georgia Emerging Infections Program, Decatur); Lucy Wilson, MD, ScM (Maryland Department of Health and Mental Hygiene, Baltimore); Jane Harper, BSN, MS, CIC, Jean Rainbow, RN, MPH, and Linn Warnke, RN, MPH (Minnesota Department of Health, St Paul); Joan Baumbach, MD, MPH, MS (New Mexico Department of Health, Santa Fe); Cathleen Concannon, MPH, and Gail Quinlan, RN, MS, CIC (New York–Rochester Emerging Infections Program/University of Rochester Medical Center, Rochester); Margaret Cunningham, MPH, Valerie Ocampo, RN, MIPH, and Jennifer Tujo, RN, MSN, MPA, CIC (Oregon Public Health Division, Oregon Health Authority, Portland); and Matthew Crist, MD, MPH (Tennessee Department of Health, Nashville).
Additional Contributions: We thank the staff and patients in each hospital that participated in phases 2 and 3 of the survey. We also thank our colleagues in the EIP sites and at the CDC who contributed to this effort and the following individuals, who received compensation for their work as CDC or EIP site employees or contractors are acknowledged for their contributions to survey coordination, data collection, and data entry: Deborah Godine, RN, CIC, and Celeste Prothro, RN, MPH (California Emerging Infections Program, Oakland); Laura McAllister-Hollod, MPH (Centers for Disease Control and Prevention, Atlanta, Georgia); Cindy Gross, MT (ASCP), SM, CIC, and Dee Higgins, RN, BSN (Georgia Emerging Infections Program, Decatur); Patricia Lawson, RN, MS, MPH, CIC, LaToya Forrester, MPH, and Malorie Givan, MPH (Maryland Department of Health and Mental Hygiene, Baltimore); Emily Hallberg, MPH (Minnesota Department of Health, St Paul); Monear Makvandi, MPH (New Mexico Department of Health, Santa Fe); Barbara Mooney, BSMB, BSMT (ASCP), CIC (Infection Control Consultants of New Mexico, consultant through HealthInsight New Mexico, Albuquerque); Jennifer Salazar, LPN (HealthInsight New Mexico, Albuquerque); Rebecca Tsay, MPH, MLS, and Anita Gellert, RN (New York–Rochester Emerging Infections Program/University of Rochester Medical Center, Rochester, NY); and Ellen Borchers, MSN, RN, Daniel Muleta, MD, MPH, Loretta Moore-Moravian, RN/BSN, COHN-S/CM, and Dana Jackson, RN, BSN (Tennessee Department of Health, Nashville).
Correction: This article was corrected on October 7, 2014, to include a link to eTable 7 in the Supplement.